akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLC10.17749/2313-7347/ob.gyn.rep.2021.274akusherstvo-1171Research ArticleREVIEW ARTICLESНАУЧНЫЕ ОБЗОРЫPlatelets, thrombo-inflammation and cancerТромбоциты, тромбовоспаление и онкологический процессhttps://orcid.org/0000-0001-7441-2778СлуханчукЕ. В.SlukhanchukE. V.

Слуханчук Екатерина Викторовна – к.м.н., доцент кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова; врач акушер-гинеколог отделения абдоминальной хирургии и онкологии 2

119991, Москва, ул. Большая Пироговская, д. 2, стр. 4119991, Москва, Абрикосовский пер., д. 2

Ekaterina V. Slukhanchuk – MD, PhD, Associate Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health; Obstetrician-Gynecologist, Department of Abdominal Surgery and Oncology 2

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow, 1199912 Abrikosovskiy Lane, Moscow, 119991

ekaterina@ginekologhirurg.ruhttps://orcid.org/0000-0001-8404-1042БицадзеВ. О.BitsadzeV. O.

Бицадзе Виктория Омаровна – д.м.н., профессор РАН, профессор кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова. Scopus Author ID: 6506003478. Researcher ID: F-8409-2017

119991, Москва, ул. Большая Пироговская, д. 2, стр. 4

Victoria O. Bitsadze – MD, Dr Sci Med, Professor of RAS, Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health. Scopus Author ID: 6506003478. Researcher ID: F-8409-2017

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow, 119991

https://orcid.org/0000-0002-0725-9686ХизроеваД. Х.KhizroevaJ. Kh.

Хизроева Джамиля Хизриевна – д.м.н., профессор кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова. Scopus Author ID: 57194547147. Researcher ID: F-8384-2017

119991, Москва, ул. Большая Пироговская, д. 2, стр. 4

Jamilya Kh. Khizroeva – MD, Dr Sci Med, Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health. Scopus Author ID: 57194547147. Researcher ID: F-8384-2017

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow, 119991

https://orcid.org/0000-0002-3628-0804ТретьяковаМ. В.TretyakovaM. V.

Третьякова Мария Владимировна – к.м.н., врач акушер-гинеколог, ассистент кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова 

119991, Москва, ул. Большая Пироговская, д. 2, стр. 4

Maria V. Tretyakova – MD, PhD, Obstetrician-Gynecologist, Assistant, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow, 119991

https://orcid.org/0000-0002-7456-2386СолоповаА. Г.SolopovaA. G.

Солопова Антонина Григорьевна – д.м.н., профессор кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова. Scopus Author ID: 6505479504. Researcher ID: Q-1385-2015

119991, Москва, ул. Большая Пироговская, д. 2, стр. 4

Antonina G. Solopova – MD, Dr Sci Med, Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children's Health. Scopus Author ID: 6505479504. Researcher ID: Q-1385-2015

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow, 119991

https://orcid.org/0000-0002-6619-6179ГалкинВ. Н.GalkinV. N.

Галкин Всеволод Николаевич – д.м.н., профессор, главный врач 

105005, Москва, Бауманская ул., д. 17/1

Vsevolod N. Galkin – MD, Dr Sci Med, Professor, Chief Physician 

17/1 Baumanskaya Str., Moscow, 105005

https://orcid.org/0000-0002-9783-1796ШкодаА. С.ShkodaA. S.

Шкода Андрей Сергеевич – д.м.н., профессор, главный врач 

123423, Москва, ул. Саляма Адиля, д. 2/44

Andrey S. Shkoda – MD, Dr Sci Med, Professor, Chief Physician 

2/44 Salyama Adilya Str., Moscow, 123423

https://orcid.org/0000-0001-5888-0774ЦибизоваВ. И.TsibizovaV. I.

Цибизова Валентина Ивановна – к.м.н., акушер-гинеколог НИЛ оперативной гинекологии Института перинатологии и педиатрии; врач отделения функциональной и ультразвуковой диагностики 

197341, Санкт-Петербург, ул. Аккуратова, д. 2

Valentina I. Tsibizova – MD, PhD, Obstetrician-Gynecologist, Research Laboratory of Operative Gynecology, Institute of Perinatology and Pediatrics; Physician, Department of Functional and Ultrasound Diagnostics 

2 Akkuratova Str., Saint Petersburg, 197341

https://orcid.org/0000-0001-6877-2777ЛинниковВ. И.LinnikovV. I.

Линников Валерий Иванович – д.м.н., профессор 

65023, Одесса, ул. Новосельского, д. 68/2

Valery I. Linnikov – MD, PhD, Professor 

68/2 Novoselskogo Str., Odessa, 65023

https://orcid.org/0000-0002-9576-1368ЭлаламиИ.ElalamyIsmail

Элалами Исмаил – д.м.н., профессор кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова; профессор; директор гематологии Центра Тромбозов. Scopus Author ID: 7003652413. Researcher ID: AAC-9695-2019

119991, Москва, ул. Большая Пироговская, д. 2, стр. 4Франция, 75006, Париж, Улица медицинского факультета, д. 12Франция, 75020, Париж, Китайская улица, д. 4

Ismail Elalamy – MD, Dr Sci Med, Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health; Professor; Director of Hematology, Department of Thrombosis Center. Scopus Author ID: 7003652413. Researcher ID: AAC-9695-2019

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow, 11999112 Rue de l’École de Médecine, Paris, 75006, France4 Rue de la Chine, Paris, 75020, France

https://orcid.org/0000-0002-9899-9910ГриЖ.-К.GrisJ.-С.

Гри Жан-Кристоф – д.м.н., профессор кафедры акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова; профессор гематологии, зав. лабораторией гематологии факультета биологических и фармацевтических наук Университета Монпелье и Университетской больницы Нима. Scopus Author ID: 7005114260. Researcher ID: AAA-2923-2019

119991, Москва, ул. Большая Пироговская, д. 2, стр. 4Франция, 34090, Монпелье, ул. Огюста Бруссоне, д. 163

Jean-Christophe Gris – MD, Dr Sci Med, Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health; Professor of Haematology, Head of the Laboratory of Haematology, Faculty of Biological and Pharmaceutical Sciences, Montpellier University and University Hospital of Nîmes. Scopus Author ID: 7005114260. Researcher ID: AAA-2923-2019

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow, 119991163 Rue Auguste Broussonnet, Montpellier, 34090, France

БреннерБ.BrennerB.

Бреннер Бенджамин – д.м.н., профессор, директор Института гематологии и трансплантации костного мозга; директор отдела внутренних болезней

31096 Хайфа, ул. Алия-а-Шния, д. 8

Benjamin Brenner – MD, Dr Sci Med, Professor, Director of the Hematology and Bone Marrow Transplantation Institute; Director of the Department of Internal Medicine

8 Aliya-ha-Shniya Str., Haifa 31096

https://orcid.org/0000-0001-7415-4633МакацарияА. Д.MakatsariyaA. D.

Макацария Александр Давидович – д.м.н., профессор, академик РАН, зав. кафедрой акушерства и гинекологии Клинического института детского здоровья имени Н.Ф. Филатова. Scopus Author ID: 57222220144. Researcher ID: M-5660-2016

119991, Москва, ул. Большая Пироговская, д. 2, стр. 4

Alexander D. Makatsariya – MD, Dr Sci Med, Academician of RAS, Professor, Head of the Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health. Scopus Author ID: 57222220144. Researcher ID: M-5660-2016

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow, 119991

ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); ФГБНУ «Российский научный центр хирургии имени академика Б.В. Петровского»РоссияSechenov University; Petrovsky National Research Centre of SurgeryRussian FederationФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияSechenov UniversityRussian FederationГБУЗ «Городская клиническая онкологическая больница № 1 Департамента здравоохранения города Москвы»РоссияCity Clinical Oncological Hospital № 1, Moscow City Healthcare DepartmentRussian FederationГБУЗ «Городская клиническая больница № 67 имени Л.А. Ворохобова Департамента здравоохранения города Москвы»РоссияVorokhobov City Clinical Hospital № 67, Moscow City Healthcare DepartmentRussian FederationФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research Centre, Health Ministry of Russian FederationRussian FederationНемецкий лечебно-диагностический центр Святого ПавлаУкраинаSaint Paul German Medical and Diagnostic CenterUkraineФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); Медицинский Университет Сорбонны; Госпиталь ТенонРоссияSechenov University; Medicine Sorbonne University; Hospital TenonRussian FederationФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); Университет МонпельеРоссияSechenov University; University of MontpellierRussian FederationАкадемический госпиталь РамбамИзраильRambam Academic HospitalIsrael202122122021156755776Copyright © Slukhanchuk E.V., Bitsadze V.O., Khizroeva J.K., Tretyakova M.V., Solopova A.G., Galkin V.N., Shkoda A.S., Tsibizova V.I., Linnikov V.I., Elalamy I., Gris J., Brenner B., Makatsariya A.D., 20222022Слуханчук Е.В., Бицадзе В.О., Хизроева Д.Х., Третьякова М.В., Солопова А.Г., Галкин В.Н., Шкода А.С., Цибизова В.И., Линников В.И., Элалами И., Гри Ж., Бреннер Б., Макацария А.Д.Slukhanchuk E.V., Bitsadze V.O., Khizroeva J.K., Tretyakova M.V., Solopova A.G., Galkin V.N., Shkoda A.S., Tsibizova V.I., Linnikov V.I., Elalamy I., Gris J., Brenner B., Makatsariya A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/1171

It has long been recognized a crucial role played by platelets in thrombosis and hemostasis. Along with that, laboratory and clinical data suggest that platelets contribute to tumor progression and metastasis through a variety of interactions with cancer cells. During oncological process, the platelet function becomes modulated via their activation and increased aggregation being one of the risk factors for developing thrombosis in cancer patients. The platelets per se enhance tumor cell dissemination, activate endothelial cells, and attract immune cells to the primary and metastatic tumor sites. In this review, we summarize the current knowledge about the complex interactions between platelets and tumor cells, as well as cells of the microenvironment, and discuss the development of new antitumor agents aimed at various arms in platelet functioning.

Всем давно известна важная роль, которую тромбоциты играют в тромбозе и гемостазе. Лабораторные и клинические данные указывают на то, что кроме этого тромбоциты способствуют прогрессии опухоли и ее метастазированию путем многообразных взаимодействий с опухолевыми клетками. На фоне онкологического процесса происходит модуляция функции тромбоцитов, повышение их активации и агрегации, что является одним из факторов риска тромбозов у онкологических больных. Сами тромбоциты усиливают диссеминацию опухолевых клеток, активируют эндотелиальные клетки, привлекают иммунные клетки к первичным и метастатическим участкам опухоли. В обзоре мы обобщаем текущие знания о сложных взаимодействиях между тромбоцитами и опухолевыми клетками, а также клетками микроокружения, обсуждаем вопросы разработки новых противоопуолевых агентов, направленных на различные звенья функционирования тромбоцитов.

тромбоцитытромбозметастазированиеопухольопухолевый ростпрогрессия опухолиplateletsthrombosismetastasistumortumor growthtumor progressionReferencesVarki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110(6):1723–9. https://doi.org/10.1182/blood2006-10-053736.Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110(6):1723–9. https://doi.org/10.1182/blood2006-10-053736.Blom J.W., Doggen C.J., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22. https://doi.org/10.1001/jama.293.6.715.Blom J.W., Doggen C.J., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22. https://doi.org/10.1001/jama.293.6.715.Duan Q., Zhang H., Zheng J., Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6(7):605–18. https://doi.org/10.1016/j.trecan.2020.02.022.Duan Q., Zhang H., Zheng J., Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6(7):605–18. https://doi.org/10.1016/j.trecan.2020.02.022.Mammadova-Bach E., Nagy M., Heemskerk J.W. et al. Store-operated calcium entry in thrombosis and thrombo-inflammation. Cell Calcium. 2019;77:39–48. https://doi.org/10.1016/j.ceca.2018.11.005.Mammadova-Bach E., Nagy M., Heemskerk J.W. et al. Store-operated calcium entry in thrombosis and thrombo-inflammation. Cell Calcium. 2019;77:39–48. https://doi.org/10.1016/j.ceca.2018.11.005.Scharf R.E. Platelet signaling in primary haemostasis and arterial thrombus formation: Part 1. Hamostaseologie. 2018;38(4):203–10. https://doi.org/10.1055/s-0038-1675144.Scharf R.E. Platelet signaling in primary haemostasis and arterial thrombus formation: Part 1. Hamostaseologie. 2018;38(4):203–10. https://doi.org/10.1055/s-0038-1675144.Silverstein M.D., Heit J.A., Mohr D.N. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585–93. https://doi.org/10.1001/archinte.158.6.585.Silverstein M.D., Heit J.A., Mohr D.N. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585–93. https://doi.org/10.1001/archinte.158.6.585.Abdel-Razeq H., Mansour A., Saadeh S.S. et al. The application of current proposed venous thromboembolism risk assessment model for ambulatory patients with cancer. Clin Appl Thromb Hemost. 2018;24(3):429–33. https://doi.org/10.1177/1076029617692880.Abdel-Razeq H., Mansour A., Saadeh S.S. et al. The application of current proposed venous thromboembolism risk assessment model for ambulatory patients with cancer. Clin Appl Thromb Hemost. 2018;24(3):429–33. https://doi.org/10.1177/1076029617692880.Patell R., Rybicki L., McCrae K.R., Khorana A.A. Predicting risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool. Am J Hematol. 2017;92(6):501–7. https://doi.org/10.1002/ajh.24700.Patell R., Rybicki L., McCrae K.R., Khorana A.A. Predicting risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool. Am J Hematol. 2017;92(6):501–7. https://doi.org/10.1002/ajh.24700.Cravioto-Villanueva A., Luna-Perez P., Gutierrez-de la Barrera M. et al. Thrombocytosis as a predictor of distant recurrence in patients with rectal cancer. Arch Med Res. 2012;43(4):305–11. https://doi.org/10.1016/j.arcmed.2012.06.008.Cravioto-Villanueva A., Luna-Perez P., Gutierrez-de la Barrera M. et al. Thrombocytosis as a predictor of distant recurrence in patients with rectal cancer. Arch Med Res. 2012;43(4):305–11. https://doi.org/10.1016/j.arcmed.2012.06.008.Stone R.L., Nick A.M., McNeish I.A. et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610–8. https://doi.org/10.1056/NEJMoa1110352.Stone R.L., Nick A.M., McNeish I.A. et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610–8. https://doi.org/10.1056/NEJMoa1110352.Kaser A., Brandacher G., Steurer W. et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis Blood. 2001;98(9):2720–5. https://doi.org/10.1182/blood.v98.9.2720.Kaser A., Brandacher G., Steurer W. et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis Blood. 2001;98(9):2720–5. https://doi.org/10.1182/blood.v98.9.2720.Besbes S., Shah S., Al-Dybiat I. et al. Thrombopoietin secretion by human ovarian cancer cells. Int J Cell Biol. 2017;2017:1873834. https://doi.org/10.1155/2017/1873834.Besbes S., Shah S., Al-Dybiat I. et al. Thrombopoietin secretion by human ovarian cancer cells. Int J Cell Biol. 2017;2017:1873834. https://doi.org/10.1155/2017/1873834.Riedl J., Hell L., Kaider A. et al. Association of platelet activation markers with cancer-associated venous thromboembolism. Platelets. 2016;27(1):80–5. https://doi.org/10.3109/09537104.2015.1041901.Riedl J., Hell L., Kaider A. et al. Association of platelet activation markers with cancer-associated venous thromboembolism. Platelets. 2016;27(1):80–5. https://doi.org/10.3109/09537104.2015.1041901.Reddel C.J., Tan C.W., Chen V.M. Thrombin generation and cancer: contributors and consequences. Cancers (Basel). 2019;11(1):100. https://doi.org/10.3390/cancers11010100.Reddel C.J., Tan C.W., Chen V.M. Thrombin generation and cancer: contributors and consequences. Cancers (Basel). 2019;11(1):100. https://doi.org/10.3390/cancers11010100.Heinmöller E., Weinel R.J., Heidtmann H.H. et al. Studies on tumor-cellinduced platelet aggregation in human lung cancer cell lines. J Cancer Res Clin Oncol. 1996;122(12):735–44. https://doi.org/10.1007/BF01209121.Heinmöller E., Weinel R.J., Heidtmann H.H. et al. Studies on tumor-cellinduced platelet aggregation in human lung cancer cell lines. J Cancer Res Clin Oncol. 1996;122(12):735–44. https://doi.org/10.1007/BF01209121.Heinmöller E., Schropp T., Kisker O. et al. Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines. Scand J Gastroenterol. 1995;30(10):1008–16. https://doi.org/10.3109/00365529509096346.Heinmöller E., Schropp T., Kisker O. et al. Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines. Scand J Gastroenterol. 1995;30(10):1008–16. https://doi.org/10.3109/00365529509096346.Gasic G.J., Gasic T.B., Stewart C.C. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 1968;61(1):46–52. https://doi.org/10.1073/pnas.61.1.46.Gasic G.J., Gasic T.B., Stewart C.C. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 1968;61(1):46–52. https://doi.org/10.1073/pnas.61.1.46.Lee H.-Y., Yu N.-Y., Lee S.-H. et al. Podoplanin promotes cancerassociated thrombosis and contributes to the unfavorable overall survival in an ectopic xenograft mouse model of oral cancer. Biomed J. 2020;43(2):146–62. https://doi.org/10.1016/j.bj.2019.07.001.Lee H.-Y., Yu N.-Y., Lee S.-H. et al. Podoplanin promotes cancerassociated thrombosis and contributes to the unfavorable overall survival in an ectopic xenograft mouse model of oral cancer. Biomed J. 2020;43(2):146–62. https://doi.org/10.1016/j.bj.2019.07.001.Lowe K.L., Navarro-Nunez L., Watson S.P. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res. 2012;129 Suppl 1:S30–7. https://doi.org/10.1016/S0049-3848(12)70013-0.Lowe K.L., Navarro-Nunez L., Watson S.P. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res. 2012;129 Suppl 1:S30–7. https://doi.org/10.1016/S0049-3848(12)70013-0.Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood. 2019;134(22):1912–8. https://doi.org/10.1182/blood.2019001388.Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood. 2019;134(22):1912–8. https://doi.org/10.1182/blood.2019001388.Zara M., Canobbio I., Visconte C. et al. Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells. Cell Signal. 2018;48:45–53. https://doi.org10.1016/j.cellsig.2018.04.008.Zara M., Canobbio I., Visconte C. et al. Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells. Cell Signal. 2018;48:45–53. https://doi.org10.1016/j.cellsig.2018.04.008.Aghourian M.N., Lemarie C.A., Bertin F.-R., Blostein M.D. Prostaglandin E synthase is upregulated by Gas6 during cancer-induced venous thrombosis. Blood. 2016;127(6):769–77. https://doi.org/10.1182/blood2015-02-628867.Aghourian M.N., Lemarie C.A., Bertin F.-R., Blostein M.D. Prostaglandin E synthase is upregulated by Gas6 during cancer-induced venous thrombosis. Blood. 2016;127(6):769–77. https://doi.org/10.1182/blood2015-02-628867.Meikle C.K., Meisler A.J., Bird C.M. et al. Platelet-T cell aggregates in lung cancer patients: Implications for thrombosis. PloS One. 2020;15(8):e0236966. https://doi.org/10.1371/journal.pone.0236966.Meikle C.K., Meisler A.J., Bird C.M. et al. Platelet-T cell aggregates in lung cancer patients: Implications for thrombosis. PloS One. 2020;15(8):e0236966. https://doi.org/10.1371/journal.pone.0236966.Rudzinski J.K., Govindasamy N.P., Lewis J.D., Jurasz P. The role of the androgen receptor in prostate cancer-induced platelet aggregation and platelet-induced invasion. J Thromb Haemost. 2020;18(11):2976–86. https://doi.org/10.1111/jth.15020.Rudzinski J.K., Govindasamy N.P., Lewis J.D., Jurasz P. The role of the androgen receptor in prostate cancer-induced platelet aggregation and platelet-induced invasion. J Thromb Haemost. 2020;18(11):2976–86. https://doi.org/10.1111/jth.15020.Mitrugno A., Williams D., Kerrigan S.W., Moran N. A novel and essential role for FcγRIIa in cancer cell–induced platelet activation. Blood. 2014;123(2):249–60. https://doi.org/10.1182/blood-2013-03-492447.Mitrugno A., Williams D., Kerrigan S.W., Moran N. A novel and essential role for FcγRIIa in cancer cell–induced platelet activation. Blood. 2014;123(2):249–60. https://doi.org/10.1182/blood-2013-03-492447.Hisada Y, Mackman N. Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models. Hematology Am Soc Hematol Educ Program. 2019;2019(1):182–6. https://doi.org/10.1182/hematology.2019000025.Hisada Y, Mackman N. Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models. Hematology Am Soc Hematol Educ Program. 2019;2019(1):182–6. https://doi.org/10.1182/hematology.2019000025.Shi C., Yang L., Braun A., Anders H.-J. Extracellular DNA – a danger signal triggering immunothrombosis. Front Immunol. 2020;11:568513. https://doi.org/10.3389/fimmu.2020.568513.Shi C., Yang L., Braun A., Anders H.-J. Extracellular DNA – a danger signal triggering immunothrombosis. Front Immunol. 2020;11:568513. https://doi.org/10.3389/fimmu.2020.568513.Wen F., Shen A., Choi A. et al. Extracellular DNA in pancreatic cancer promotes cell invasion and metastasis. Cancer Res. 2013;73(14):4256–66. https://doi.org/10.1158/0008-5472.CAN-12-3287.Wen F., Shen A., Choi A. et al. Extracellular DNA in pancreatic cancer promotes cell invasion and metastasis. Cancer Res. 2013;73(14):4256–66. https://doi.org/10.1158/0008-5472.CAN-12-3287.Eelen G., Treps L., Li X., Carmeliet P. Basic and therapeutic aspects of angiogenesis updated. Circ Res. 2020;127(2):310–29. https://doi.org/10.1161/CIRCRESAHA.120.316851.Eelen G., Treps L., Li X., Carmeliet P. Basic and therapeutic aspects of angiogenesis updated. Circ Res. 2020;127(2):310–29. https://doi.org/10.1161/CIRCRESAHA.120.316851.Goubran H.A., Burnouf T., Radosevic M., El-Ekiaby M. The platelet–cancer loop. Eur J Inter Med. 2013;24(5):393–400. https://doi.org/10.1016/j.ejim.2013.01.017.Goubran H.A., Burnouf T., Radosevic M., El-Ekiaby M. The platelet–cancer loop. Eur J Inter Med. 2013;24(5):393–400. https://doi.org/10.1016/j.ejim.2013.01.017.Zaslavsky A., Baek K.-H., Lynch R.C. et al. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood. 2010;115(22):4605–13. https://doi.org/10.1182/blood-2009-09-242065.Zaslavsky A., Baek K.-H., Lynch R.C. et al. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood. 2010;115(22):4605–13. https://doi.org/10.1182/blood-2009-09-242065.Battinelli E.M., Markens B.A., Italiano J.E. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood. 2011;118(5):1359–69. https://doi.org/10.1182/blood-2011-02-334524.Battinelli E.M., Markens B.A., Italiano J.E. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood. 2011;118(5):1359–69. https://doi.org/10.1182/blood-2011-02-334524.Salgado R., Junius S., Benoy I. et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103(5):642–6. https://doi.org/10.1002/ijc.10833.Salgado R., Junius S., Benoy I. et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103(5):642–6. https://doi.org/10.1002/ijc.10833.Feng W., Madajka M., Kerr B.A. et al. A novel role for platelet secretion in angiogenesis: mediating bone marrow–derived cell mobilization and homing. Blood. 2011;117(14):3892–902. https://doi.org/10.1182/blood2010-08-304808.Feng W., Madajka M., Kerr B.A. et al. A novel role for platelet secretion in angiogenesis: mediating bone marrow–derived cell mobilization and homing. Blood. 2011;117(14):3892–902. https://doi.org/10.1182/blood2010-08-304808.Kuznetsov H.S., Marsh T., Markens B.A. et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow–derived cells. Cancer Discov. 2012;2(12):1150–65. https://doi.org/10.1158/2159-8290.CD-12-0216.Kuznetsov H.S., Marsh T., Markens B.A. et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow–derived cells. Cancer Discov. 2012;2(12):1150–65. https://doi.org/10.1158/2159-8290.CD-12-0216.Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13(1):9–22.Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13(1):9–22.Wojtukiewicz M.Z., Sierko E., Hempel D. et al. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev. 2017;36(2):249–62. https://doi.org/10.1007/s10555-017-9673-1.Wojtukiewicz M.Z., Sierko E., Hempel D. et al. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev. 2017;36(2):249–62. https://doi.org/10.1007/s10555-017-9673-1.Borgström P., Discipio R., Maione T. Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma. Anticancer Res. 1998;18(6A):4035–41.Borgström P., Discipio R., Maione T. Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma. Anticancer Res. 1998;18(6A):4035–41.Varner J.A., Nakada M.T., Jordan R.E., Coller B.S. Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibodyof c7E3 Fab (abciximab; ReoProTM). Angiogenesis. 1999;3(1):53–60. https://doi.org/10.1023/a:1009019223744.Varner J.A., Nakada M.T., Jordan R.E., Coller B.S. Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibodyof c7E3 Fab (abciximab; ReoProTM). Angiogenesis. 1999;3(1):53–60. https://doi.org/10.1023/a:1009019223744.Huang Z., Miao X., Patarroyo M. et al. Tetraspanin CD 151 and integrin α6β1 mediate platelet-enhanced endothelial colony forming cell angiogenesis. J Thromb Haemost. 2016;14(3):606–18. https://doi.org/10.1111/jth.13248.Huang Z., Miao X., Patarroyo M. et al. Tetraspanin CD 151 and integrin α6β1 mediate platelet-enhanced endothelial colony forming cell angiogenesis. J Thromb Haemost. 2016;14(3):606–18. https://doi.org/10.1111/jth.13248.Anene C., Graham A.M., Boyne J., Roberts W. Platelet microparticle delivered microRNA-Let-7a promotes the angiogenic switch. Biochim Biophys Acta Mol Basis Dis. 2018;1864(8):2633–43. https://doi.org/10.1016/j.bbadis.2018.04.013.Anene C., Graham A.M., Boyne J., Roberts W. Platelet microparticle delivered microRNA-Let-7a promotes the angiogenic switch. Biochim Biophys Acta Mol Basis Dis. 2018;1864(8):2633–43. https://doi.org/10.1016/j.bbadis.2018.04.013.Bertozzi C.C., Schmaier A.A., Mericko P. et al. Platelets regulate lymphatic vascular development through CLEC-2–SLP-76 signaling. Blood. 2010;116(4):661–70. https://doi.org/10.1182/blood-2010-02-270876.Bertozzi C.C., Schmaier A.A., Mericko P. et al. Platelets regulate lymphatic vascular development through CLEC-2–SLP-76 signaling. Blood. 2010;116(4):661–70. https://doi.org/10.1182/blood-2010-02-270876.Haining E.J., Lowe K.L., Wichaiyo S. et al. Lymphatic blood filling in CLEC2-deficient mouse models. Platelets. 2021;32(3):352–67. https://doi.org/10.1080/09537104.2020.1734784.Haining E.J., Lowe K.L., Wichaiyo S. et al. Lymphatic blood filling in CLEC2-deficient mouse models. Platelets. 2021;32(3):352–67. https://doi.org/10.1080/09537104.2020.1734784.Martini C., Thompson E.J., Hyslop S.R. et al. Platelets disrupt vasculogenic mimicry by cancer cells. Scientific Reports. 2020;10(1):1–18. https://doi.org/10.1038/s41598-020-62648-x.Martini C., Thompson E.J., Hyslop S.R. et al. Platelets disrupt vasculogenic mimicry by cancer cells. Scientific Reports. 2020;10(1):1–18. https://doi.org/10.1038/s41598-020-62648-x.Ho-Tin-Noé B., Goerge T., Cifuni S.M. et al. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res. 2008;68(16):6851–8. https://doi.org/10.1158/0008-5472.CAN-08-0718.Ho-Tin-Noé B., Goerge T., Cifuni S.M. et al. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res. 2008;68(16):6851–8. https://doi.org/10.1158/0008-5472.CAN-08-0718.Demers M., Ho-Tin-Noé B., Schatzberg D. et al. Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res. 2011;71(5):1540–9. https://doi.org/10.1158/0008-5472.CAN-10-2038.Demers M., Ho-Tin-Noé B., Schatzberg D. et al. Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res. 2011;71(5):1540–9. https://doi.org/10.1158/0008-5472.CAN-10-2038.Volz J., Mammadova-Bach E., Gil-Pulido J. et al. Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of chemotherapy in mice. Blood. 2019;133(25):2696–706. https://doi.org/10.1182/blood.2018877043.Volz J., Mammadova-Bach E., Gil-Pulido J. et al. Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of chemotherapy in mice. Blood. 2019;133(25):2696–706. https://doi.org/10.1182/blood.2018877043.Camerer E., Qazi A.A., Duong D.N. et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004;104(2):397–401. https://doi.org/10.1182/blood-2004-02-0434.Camerer E., Qazi A.A., Duong D.N. et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004;104(2):397–401. https://doi.org/10.1182/blood-2004-02-0434.Palumbo J.S., Talmage K.E., Massari J.V. et al. Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell–mediated elimination of tumor cells. Blood. 2005;105(1):178–85. https://doi.org/10.1182/blood-2004-06-2272.Palumbo J.S., Talmage K.E., Massari J.V. et al. Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell–mediated elimination of tumor cells. Blood. 2005;105(1):178–85. https://doi.org/10.1182/blood-2004-06-2272.Coupland L.A., Chong B.H., Parish C.R. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res. 2012;72(18):4662–71. https://doi.org/10.1158/0008-5472.CAN-11-4010.Coupland L.A., Chong B.H., Parish C.R. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res. 2012;72(18):4662–71. https://doi.org/10.1158/0008-5472.CAN-11-4010.Placke T., Örgel M., Schaller M. et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–8. https://doi.org/10.1158/0008-5472.CAN-11-1872.Placke T., Örgel M., Schaller M. et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–8. https://doi.org/10.1158/0008-5472.CAN-11-1872.Maurer S., Kropp K.N., Klein G. et al. Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. Oncoimmunology. 2017;7(2):e1364827. https://doi.org/10.1080/2162402X.2017.1364827.Maurer S., Kropp K.N., Klein G. et al. Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. Oncoimmunology. 2017;7(2):e1364827. https://doi.org/10.1080/2162402X.2017.1364827.Kopp H.-G., Placke T., Salih H.R. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69(19):7775–83. https://doi.org/10.1158/0008-5472.Kopp H.-G., Placke T., Salih H.R. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69(19):7775–83. https://doi.org/10.1158/0008-5472.Rachidi S., Metelli A., Riesenberg B. et al. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci Immunol. 2017;2(11):eaai7911. https://doi.org/10.1126/sciimmunol.aai7911.Rachidi S., Metelli A., Riesenberg B. et al. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci Immunol. 2017;2(11):eaai7911. https://doi.org/10.1126/sciimmunol.aai7911.Metelli A., Wu B.X., Riesenberg B. et al. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β. Sci Transl Med. 2020;12(525):eaay4860. https://doi.org/10.1126/scitranslmed.aay4860.Metelli A., Wu B.X., Riesenberg B. et al. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β. Sci Transl Med. 2020;12(525):eaay4860. https://doi.org/10.1126/scitranslmed.aay4860.Huynh L.K., Hipolito C.J., Ten Dijke P. A perspective on the development of TGF-β inhibitors for cancer treatment. Biomolecules. 2019;9(11):743. https://doi.org/10.3390/biom9110743.Huynh L.K., Hipolito C.J., Ten Dijke P. A perspective on the development of TGF-β inhibitors for cancer treatment. Biomolecules. 2019;9(11):743. https://doi.org/10.3390/biom9110743.Kalos M., June C.H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49–60. https://doi.org/10.1016/j.immuni.2013.07.002.Kalos M., June C.H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49–60. https://doi.org/10.1016/j.immuni.2013.07.002.Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–90. https://doi.org/10.1016/j.ccr.2011.09.009.Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–90. https://doi.org/10.1016/j.ccr.2011.09.009.Xiong G., Chen J., Zhang G. et al. Hsp47 promotes cancer metastasis by enhancing collagen-dependent cancer cell-platelet interaction. Proc Natl Acad Sci U S A. 2020;117(7):3748–58. https://doi.org/10.1073/pnas.1911951117.Xiong G., Chen J., Zhang G. et al. Hsp47 promotes cancer metastasis by enhancing collagen-dependent cancer cell-platelet interaction. Proc Natl Acad Sci U S A. 2020;117(7):3748–58. https://doi.org/10.1073/pnas.1911951117.Zuo X.-X., Yang Y., Zhang Y. et al. Platelets promote breast cancer cell MCF-7 metastasis by direct interaction: surface integrin α2β1-contactingmediated activation of Wnt-β-catenin pathway. Cell Commun Signal. 2019;17(1):1–15. https://doi.org/10.1186/s12964-019-0464-x.Zuo X.-X., Yang Y., Zhang Y. et al. Platelets promote breast cancer cell MCF-7 metastasis by direct interaction: surface integrin α2β1-contactingmediated activation of Wnt-β-catenin pathway. Cell Commun Signal. 2019;17(1):1–15. https://doi.org/10.1186/s12964-019-0464-x.Steinbrecher K.A., Horowitz N.A., Blevins E.A. et al. Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen. Cancer Res. 2010;70(7):2634–43. https://doi.org/10.1158/0008-5472.CAN-09-3465.Steinbrecher K.A., Horowitz N.A., Blevins E.A. et al. Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen. Cancer Res. 2010;70(7):2634–43. https://doi.org/10.1158/0008-5472.CAN-09-3465.Andrade S.S., Gouvea I.E., Silva M.C.C. et al. Cathepsin K induces platelet dysfunction and affects cell signaling in breast cancer-molecularly distinct behavior of cathepsin K in breast cancer. BMC Cancer. 2016;16:173. https://doi.org/10.1186/s12885-016-2203-7.Andrade S.S., Gouvea I.E., Silva M.C.C. et al. Cathepsin K induces platelet dysfunction and affects cell signaling in breast cancer-molecularly distinct behavior of cathepsin K in breast cancer. BMC Cancer. 2016;16:173. https://doi.org/10.1186/s12885-016-2203-7.Tang M., Jiang L., Lin Y. et al. Platelet microparticle-mediated transfer of miR-939 to epithelial ovarian cancer cells promotes epithelial to mesenchymal transition. Oncotarget. 2017;8(57):97464–75. https://doi.org/10.18632/oncotarget.22136.Tang M., Jiang L., Lin Y. et al. Platelet microparticle-mediated transfer of miR-939 to epithelial ovarian cancer cells promotes epithelial to mesenchymal transition. Oncotarget. 2017;8(57):97464–75. https://doi.org/10.18632/oncotarget.22136.Qi C.-L., Wei B., Ye J. et al. P-selectin-mediated platelet adhesion promotes the metastasis of murine melanoma cells. PloS One. 2014;9(3):e91320. https://doi.org/10.1371/journal.pone.0091320.Qi C.-L., Wei B., Ye J. et al. P-selectin-mediated platelet adhesion promotes the metastasis of murine melanoma cells. PloS One. 2014;9(3):e91320. https://doi.org/10.1371/journal.pone.0091320.Zimmerman G.A. Two by two: the pairings of P-selectin and P-selectin glycoprotein ligand 1. Proc Natl Acad Sci U S A. 2001;98(18):10023–4. https://doi.org/10.1073/pnas.191367898.Zimmerman G.A. Two by two: the pairings of P-selectin and P-selectin glycoprotein ligand 1. Proc Natl Acad Sci U S A. 2001;98(18):10023–4. https://doi.org/10.1073/pnas.191367898.Qi Y., Chen W., Liang X. et al. Novel antibodies against GPIbα inhibit pulmonary metastasis by affecting vWF-GPIbα interaction. J Hematol Oncol. 2018;11(1):117. https://doi.org/10.1186/s13045-018-0659-4.Qi Y., Chen W., Liang X. et al. Novel antibodies against GPIbα inhibit pulmonary metastasis by affecting vWF-GPIbα interaction. J Hematol Oncol. 2018;11(1):117. https://doi.org/10.1186/s13045-018-0659-4.Morimoto K., Satoh-Yamaguchi K., Hamaguchi A. et al. Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs. Oncogene. 2008;27(3):264–73. https://doi.org/10.1038/sj.onc.1210645.Morimoto K., Satoh-Yamaguchi K., Hamaguchi A. et al. Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs. Oncogene. 2008;27(3):264–73. https://doi.org/10.1038/sj.onc.1210645.Peyruchaud O., Saier L., Leblanc R. Autotaxin implication in cancer metastasis and autoimunne disorders: functional implication of binding autotaxin to the cell surface. Cancers (Basel). 2019;12(1):105. https://doi.org/10.3390/cancers12010105.Peyruchaud O., Saier L., Leblanc R. Autotaxin implication in cancer metastasis and autoimunne disorders: functional implication of binding autotaxin to the cell surface. Cancers (Basel). 2019;12(1):105. https://doi.org/10.3390/cancers12010105.Im J.H., Fu W., Wang H. et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 2004;64(23):8613–9. https://doi.org/10.1158/0008-5472.CAN-04-2078.Im J.H., Fu W., Wang H. et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 2004;64(23):8613–9. https://doi.org/10.1158/0008-5472.CAN-04-2078.Schumacher D., Strilic B., Sivaraj K.K. et al. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013;24(1):130–7. https://doi.org/10.1016/j.ccr.2013.05.008.Schumacher D., Strilic B., Sivaraj K.K. et al. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013;24(1):130–7. https://doi.org/10.1016/j.ccr.2013.05.008.Bambace N.M., Levis J.E., Holmes C.E. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets. 2010;21(2):85–93. https://doi.org/10.3109/09537100903470298.Bambace N.M., Levis J.E., Holmes C.E. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets. 2010;21(2):85–93. https://doi.org/10.3109/09537100903470298.Mammadova-Bach E., Gil-Pulido J., Sarukhanyan E. et al. Platelet glycoprotein VI promotes metastasis through interaction with cancer cell–derived galectin-3. Blood. 2020;135(14):1146–60. https://doi.org/10.1182/blood.2019002649.Mammadova-Bach E., Gil-Pulido J., Sarukhanyan E. et al. Platelet glycoprotein VI promotes metastasis through interaction with cancer cell–derived galectin-3. Blood. 2020;135(14):1146–60. https://doi.org/10.1182/blood.2019002649.Chang C.-N., Feng M.-J., Chen Y.-L. et al. p15PAF is an Rb/E2F-regulated S-phase protein essential for DNA synthesis and cell cycle progression. PloS One. 2013;8(4):e61196. https://doi.org/10.1371/journal.pone.0061196.Chang C.-N., Feng M.-J., Chen Y.-L. et al. p15PAF is an Rb/E2F-regulated S-phase protein essential for DNA synthesis and cell cycle progression. PloS One. 2013;8(4):e61196. https://doi.org/10.1371/journal.pone.0061196.Guerrero J.A., Bennett C., van der Weyden L. et al. Gray platelet syndrome: proinflammatory megakaryocytes and α-granule loss cause myelofibrosis and confer metastasis resistance in mice. Blood. 2014;124(24):3624–35. https://doi.org/10.1182/blood-2014-04-566760.Guerrero J.A., Bennett C., van der Weyden L. et al. Gray platelet syndrome: proinflammatory megakaryocytes and α-granule loss cause myelofibrosis and confer metastasis resistance in mice. Blood. 2014;124(24):3624–35. https://doi.org/10.1182/blood-2014-04-566760.Mammadova-Bach E., Zigrino P., Brucker C. et al. Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell–derived ADAM9. JCI Insight. 2016;1(14):e88245. https://doi.org/10.1172/jci.insight.88245.Mammadova-Bach E., Zigrino P., Brucker C. et al. Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell–derived ADAM9. JCI Insight. 2016;1(14):e88245. https://doi.org/10.1172/jci.insight.88245.Yu L.-X., Yan L., Yang W. et al. Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein. Nat Commun. 2014;5:52–6. https://doi.org/10.1038/ncomms6256.Yu L.-X., Yan L., Yang W. et al. Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein. Nat Commun. 2014;5:52–6. https://doi.org/10.1038/ncomms6256.Li R., Ren M., Chen N. et al. Presence of intratumoral platelets is associated with tumor vessel structure and metastasis. BMC Cancer. 2014;14:167. https://doi.org/10.1186/1471-2407-14-167.Li R., Ren M., Chen N. et al. Presence of intratumoral platelets is associated with tumor vessel structure and metastasis. BMC Cancer. 2014;14:167. https://doi.org/10.1186/1471-2407-14-167.Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell. 2016;30(5):668–81. https://doi.org/10.1016/j.ccell.2016.09.011.Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell. 2016;30(5):668–81. https://doi.org/10.1016/j.ccell.2016.09.011.Labelle M., Begum S., Hynes R.O. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A. 2014;111(30):E3053–61. https://doi.org/10.1073/pnas.1411082111.Labelle M., Begum S., Hynes R.O. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A. 2014;111(30):E3053–61. https://doi.org/10.1073/pnas.1411082111.Lucotti S., Cerutti C., Soyer M. et al. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. J Clin Invest. 2019;129(5):1845–62. https://doi.org/10.1172/JCI121985.Lucotti S., Cerutti C., Soyer M. et al. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. J Clin Invest. 2019;129(5):1845–62. https://doi.org/10.1172/JCI121985.Catena R., Bhattacharya N., El Rayes T. et al. Bone marrow–derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 2013;3(5):578–89. https://doi.org/10.1158/2159-8290.CD-12-0476.Catena R., Bhattacharya N., El Rayes T. et al. Bone marrow–derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 2013;3(5):578–89. https://doi.org/10.1158/2159-8290.CD-12-0476.Kerr B.A., Harris K.S., Shi L. et al. Platelet TSP-1 controls prostate cancerinduced osteoclast differentiation and bone marrow-derived cell mobilization through TGFβ-1. Am J Clin Exp Urol. 2021;9(1):18–31.Kerr B.A., Harris K.S., Shi L. et al. Platelet TSP-1 controls prostate cancerinduced osteoclast differentiation and bone marrow-derived cell mobilization through TGFβ-1. Am J Clin Exp Urol. 2021;9(1):18–31.De Arcangelis A., Hamade H., Alpy F. et al. Hemidesmosome integrity protects the colon against colitis and colorectal cancer. Gut. 2017;66(10):1748–60. https://doi.org/10.1136/gutjnl-2015-310847.De Arcangelis A., Hamade H., Alpy F. et al. Hemidesmosome integrity protects the colon against colitis and colorectal cancer. Gut. 2017;66(10):1748–60. https://doi.org/10.1136/gutjnl-2015-310847.Durrant T.N., van den Bosch M.T., Hers I. Integrin αIIbβ3 outside-in signaling. Blood. 2017;130(14):1607–19. https://doi.org/10.1182/blood2017-03-773614.Durrant T.N., van den Bosch M.T., Hers I. Integrin αIIbβ3 outside-in signaling. Blood. 2017;130(14):1607–19. https://doi.org/10.1182/blood2017-03-773614.Boucharaba A., Serre C.-M., Grès S. et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004;114(12):1714–25. https://doi.org/10.1172/JCI22123.Boucharaba A., Serre C.-M., Grès S. et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004;114(12):1714–25. https://doi.org/10.1172/JCI22123.Echtler K., Konrad I., Lorenz M. et al. Platelet GPIIb supports initial pulmonary retention but inhibits subsequent proliferation of melanoma cells during hematogenic metastasis. PloS One. 2017;12(3):e0172788. https://doi.org/10.1371/journal.pone.0172788.Echtler K., Konrad I., Lorenz M. et al. Platelet GPIIb supports initial pulmonary retention but inhibits subsequent proliferation of melanoma cells during hematogenic metastasis. PloS One. 2017;12(3):e0172788. https://doi.org/10.1371/journal.pone.0172788.Tímar J., Tovari J., Raso E. et al. Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology. 2005;69(3):185–201. https://doi.org/10.1159/000088069.Tímar J., Tovari J., Raso E. et al. Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology. 2005;69(3):185–201. https://doi.org/10.1159/000088069.Zhu G., Zhang Q., Reddy E.C. et al. The integrin PSI domain has an endogenous thiol isomerase function and is a novel target for antiplatelet therapy. Blood. 2017;129(13):1840–54. https://doi.org/10.1182/blood2016-07-729400.Zhu G., Zhang Q., Reddy E.C. et al. The integrin PSI domain has an endogenous thiol isomerase function and is a novel target for antiplatelet therapy. Blood. 2017;129(13):1840–54. https://doi.org/10.1182/blood2016-07-729400.Jain S., Zuka M., Liu J. et al. Platelet glycoprotein Ibα supports experimental lung metastasis. Proc Natl Acad Sci U S A. 2007;104(21):9024–8. https://doi.org/10.1073/pnas.0700625104.Jain S., Zuka M., Liu J. et al. Platelet glycoprotein Ibα supports experimental lung metastasis. Proc Natl Acad Sci U S A. 2007;104(21):9024–8. https://doi.org/10.1073/pnas.0700625104.Erpenbeck L., Nieswandt B., Schön M. et al. Inhibition of platelet GPIb alpha and promotion of melanoma metastasis. J Invest Dermatol. 2010;130(2):576–86. https://doi.org/10.1038/jid.2009.278.Erpenbeck L., Nieswandt B., Schön M. et al. Inhibition of platelet GPIb alpha and promotion of melanoma metastasis. J Invest Dermatol. 2010;130(2):576–86. https://doi.org/10.1038/jid.2009.278.Malehmir M., Pfister D., Gallage S. et al. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med. 2019;25(4):641–55. https://doi.org/10.1038/s41591-019-0379-5.Malehmir M., Pfister D., Gallage S. et al. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med. 2019;25(4):641–55. https://doi.org/10.1038/s41591-019-0379-5.Ungerer M., Rosport K., Bültmann A. et al. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collageninduced platelet aggregation without affecting general hemostasis in humans. Circulation. 2011;123(17):1891–9. https://doi.org/10.1161/CIRCULATIONAHA.110.980623.Ungerer M., Rosport K., Bültmann A. et al. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collageninduced platelet aggregation without affecting general hemostasis in humans. Circulation. 2011;123(17):1891–9. https://doi.org/10.1161/CIRCULATIONAHA.110.980623.Kato Y., Kaneko M.K. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep. 2014;4(1):1–9. https://doi.org/10.1038/srep05924.Kato Y., Kaneko M.K. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep. 2014;4(1):1–9. https://doi.org/10.1038/srep05924.Xu M., Wang X., Pan Y. et al. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma. BMC Cancer. 2019;19(1):599. https://doi.org/10.1186/s12885-019-5808-9.Xu M., Wang X., Pan Y. et al. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma. BMC Cancer. 2019;19(1):599. https://doi.org/10.1186/s12885-019-5808-9.Sekiguchi T., Takemoto A., Takagi S. et al. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget. 2016;7(4):3934. https://doi.org/10.18632/oncotarget.6598.Sekiguchi T., Takemoto A., Takagi S. et al. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget. 2016;7(4):3934. https://doi.org/10.18632/oncotarget.6598.Koki A.T., Masferrer J.L. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control. 2002;9(2 Suppl):28–35. https://doi.org/10.1177/107327480200902S04.Koki A.T., Masferrer J.L. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control. 2002;9(2 Suppl):28–35. https://doi.org/10.1177/107327480200902S04.Gasic G.J., Gasic T.B., Galanti N. et al. Platelet–tumor–cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer. 1973;11(3):704–18. https://doi.org/10.1002/ijc.2910110322.Gasic G.J., Gasic T.B., Galanti N. et al. Platelet–tumor–cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer. 1973;11(3):704–18. https://doi.org/10.1002/ijc.2910110322.Kune G.A., Kune S., Watson L.F. Colorectal cancer risk, chronic illnesses, operations and medications: case–control results from the Melbourne Colorectal Cancer Study. 1988. Int J Epidemiol. 2007;36(5):951–7. https://doi.org/10.1093/ije/dym193.Kune G.A., Kune S., Watson L.F. Colorectal cancer risk, chronic illnesses, operations and medications: case–control results from the Melbourne Colorectal Cancer Study. 1988. Int J Epidemiol. 2007;36(5):951–7. https://doi.org/10.1093/ije/dym193.Benamouzig R., Deyra J., Martin A. et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125(2):328–36. https://doi.org/10.1016/s0016-5085(03)00887-4.Benamouzig R., Deyra J., Martin A. et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125(2):328–36. https://doi.org/10.1016/s0016-5085(03)00887-4.Ishikawa H., Wakabayashi K., Suzuki S. et al. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med. 2013;2(1):50–6. https://doi.org/10.1002/cam4.46.Ishikawa H., Wakabayashi K., Suzuki S. et al. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med. 2013;2(1):50–6. https://doi.org/10.1002/cam4.46.Burn J., Gerdes A.-M., Macrae F. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–7. https://doi.org/10.1016/S0140-6736(11)61049-0.Burn J., Gerdes A.-M., Macrae F. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–7. https://doi.org/10.1016/S0140-6736(11)61049-0.Frouws M., Bastiaannet E., Langley R. et al. Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study. Br J Cancer. 2017;116(3):405–13. https://doi.org/10.1038/bjc.2016.425.Frouws M., Bastiaannet E., Langley R. et al. Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study. Br J Cancer. 2017;116(3):405–13. https://doi.org/10.1038/bjc.2016.425.Rothwell P.M., Price J.F., Fowkes F.G.R. et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–12. https://doi.org/10.1016/S0140-6736(11)61720-0.Rothwell P.M., Price J.F., Fowkes F.G.R. et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–12. https://doi.org/10.1016/S0140-6736(11)61720-0.Lecomte M., Laneuville O., Ji C. et al. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem. 1994;269(18):13207–15.Lecomte M., Laneuville O., Ji C. et al. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem. 1994;269(18):13207–15.Cazenave J.-P., Gachet C. Anti-platelet drugs: do they affect megakaryocytes? Baillieres Clin Haematol. 1997;10(1):163–80. https://doi.org/10.1016/s0950-3536(97)80056-x.Cazenave J.-P., Gachet C. Anti-platelet drugs: do they affect megakaryocytes? Baillieres Clin Haematol. 1997;10(1):163–80. https://doi.org/10.1016/s0950-3536(97)80056-x.Lucotti S., Muschel R.J. Platelets and metastasis: new implications of an old interplay. Front Oncol. 2020;10:1350. https://doi.org/10.3389/fonc.2020.01350.Lucotti S., Muschel R.J. Platelets and metastasis: new implications of an old interplay. Front Oncol. 2020;10:1350. https://doi.org/10.3389/fonc.2020.01350.Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost. 2008;99(3):466–72. https://doi.org/10.1160/TH07-11-0673.Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost. 2008;99(3):466–72. https://doi.org/10.1160/TH07-11-0673.Mezouar S., Darbousset R., Dignat-George F. et al. Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Int J Cancer. 2015;136(2):462–75. https://doi.org/10.1002/ijc.28997.Mezouar S., Darbousset R., Dignat-George F. et al. Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Int J Cancer. 2015;136(2):462–75. https://doi.org/10.1002/ijc.28997.Gareau A.J., Brien C., Gebremeskel S. et al. Ticagrelor inhibits platelet–tumor cell interactions and metastasis in human and murine breast cancer. Clin Exp Metastasis. 2018;35(1–2):25–35. https://doi.org/10.1007/s10585-018-9874-1.Gareau A.J., Brien C., Gebremeskel S. et al. Ticagrelor inhibits platelet–tumor cell interactions and metastasis in human and murine breast cancer. Clin Exp Metastasis. 2018;35(1–2):25–35. https://doi.org/10.1007/s10585-018-9874-1.Cho M.S., Noh K., Haemmerle M. et al. Role of ADP receptors on platelets in the growth of ovarian cancer. Blood. 2017;130(10):1235–42. https://doi.org/10.1182/blood-2017-02-769893.Cho M.S., Noh K., Haemmerle M. et al. Role of ADP receptors on platelets in the growth of ovarian cancer. Blood. 2017;130(10):1235–42. https://doi.org/10.1182/blood-2017-02-769893.Geranpayehvaghei M., Shi Q., Zhao B. et al. Targeting delivery of platelets inhibitor to prevent tumor metastasis. Bioconjug Chem. 2019;30(9):2349–57. https://doi.org/10.1021/acs.bioconjchem.9b00457.Geranpayehvaghei M., Shi Q., Zhao B. et al. Targeting delivery of platelets inhibitor to prevent tumor metastasis. Bioconjug Chem. 2019;30(9):2349–57. https://doi.org/10.1021/acs.bioconjchem.9b00457.Elaskalani O., Falasca M., Moran N. et al. The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistance. Cancers (Basel). 2017;9(10):142. https://doi.org/10.3390/cancers9100142.Elaskalani O., Falasca M., Moran N. et al. The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistance. Cancers (Basel). 2017;9(10):142. https://doi.org/10.3390/cancers9100142.Denslow A., Switalska M., Jarosz J. et al. Clopidogrel in a combined therapy with anticancer drugs—effect on tumor growth, metastasis, and treatment toxicity: studies in animal models. PLoS One. 2017;12(12):e0188740. https://doi.org/10.1371/journal.pone.0188740.Denslow A., Switalska M., Jarosz J. et al. Clopidogrel in a combined therapy with anticancer drugs—effect on tumor growth, metastasis, and treatment toxicity: studies in animal models. PLoS One. 2017;12(12):e0188740. https://doi.org/10.1371/journal.pone.0188740.Su X., Floyd D.H., Hughes A. et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest. 2012;122(10):3579–92. https://doi.org/10.1172/JCI38576.Su X., Floyd D.H., Hughes A. et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest. 2012;122(10):3579–92. https://doi.org/10.1172/JCI38576.Cheng J.W. Impact of selective platelet inhibition in reducing cardiovascular risk–role of vorapaxar. Vasc Health Risk Manag. 2016;12:263–8. https://doi.org/10.2147/VHRM.S81342.Cheng J.W. Impact of selective platelet inhibition in reducing cardiovascular risk–role of vorapaxar. Vasc Health Risk Manag. 2016;12:263–8. https://doi.org/10.2147/VHRM.S81342.Aisiku O., Peters C.G., De Ceunynck K. et al. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood. 2015;125(12):1976–85. https://doi.org/10.1182/blood-2014-09-599910.Aisiku O., Peters C.G., De Ceunynck K. et al. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood. 2015;125(12):1976–85. https://doi.org/10.1182/blood-2014-09-599910.Ma S.-N., Mao Z.-X., Wu Y. et al. The anti-cancer properties of heparin and its derivatives: a review and prospect. Cell Adhesion & Migration. 2020;14(1):118–28. https://doi.org/10.1080/19336918.2020.Ma S.-N., Mao Z.-X., Wu Y. et al. The anti-cancer properties of heparin and its derivatives: a review and prospect. Cell Adhesion & Migration. 2020;14(1):118–28. https://doi.org/10.1080/19336918.2020.Azab A.K., Quang P., Azab F. et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012;119(6):1468–78. https://doi.org/10.1182/blood-2011-07-368050.Azab A.K., Quang P., Azab F. et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012;119(6):1468–78. https://doi.org/10.1182/blood-2011-07-368050.Gardner R. Crizanlizumab in vaso-occlusive crisis caused by sickle cell disease. Drugs Today (Barc). 2020;56(11):705–14. https://doi.org/10.1358/dot.2020.56.11.3178111.Gardner R. Crizanlizumab in vaso-occlusive crisis caused by sickle cell disease. Drugs Today (Barc). 2020;56(11):705–14. https://doi.org/10.1358/dot.2020.56.11.3178111.Peterson J.E., Zurakowski D., Italiano J.E. et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012;15(2):265–73. https://doi.org/10.1007/s10456-012-9259-z.Peterson J.E., Zurakowski D., Italiano J.E. et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012;15(2):265–73. https://doi.org/10.1007/s10456-012-9259-z.Best M., Sol N., Kooi I. et al. RNA-seq of tumor-educated platelets enables article RNA-seq of tumor-educated platelets enables. Cancer Cell. 2015;28(5):666–76. https://doi.org/10.1016/j.ccell.2015.09.018.Best M., Sol N., Kooi I. et al. RNA-seq of tumor-educated platelets enables article RNA-seq of tumor-educated platelets enables. Cancer Cell. 2015;28(5):666–76. https://doi.org/10.1016/j.ccell.2015.09.018.Best M.G., Wesseling P., Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Cancer Res. 2018;78(13):3407–12. https://doi.org/10.1158/0008-5472.CAN-18-0887.Best M.G., Wesseling P., Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Cancer Res. 2018;78(13):3407–12. https://doi.org/10.1158/0008-5472.CAN-18-0887.Dai H., Zhou H., Sun Y. et al. D-dimer as a potential clinical marker for predicting metastasis and progression in cancer. Biomed Rep. 2018;9(5):453–7. https://doi.org/10.3892/br.2018.1151.Dai H., Zhou H., Sun Y. et al. D-dimer as a potential clinical marker for predicting metastasis and progression in cancer. Biomed Rep. 2018;9(5):453–7. https://doi.org/10.3892/br.2018.1151.Geddings J.E., Mackman N. Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122(11):1873–80. https://doi.org/10.1182/blood-2013-04-460139.Geddings J.E., Mackman N. Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122(11):1873–80. https://doi.org/10.1182/blood-2013-04-460139.Ibele G.M., Kay N.E., Johnson G.J., Jacob H.S. Human platelets exert cytotoxic effects on tumor cells. Blood. 1985;65(5):1252–5.Ibele G.M., Kay N.E., Johnson G.J., Jacob H.S. Human platelets exert cytotoxic effects on tumor cells. Blood. 1985;65(5):1252–5.Sagawa T., Tominaga A., Kodama T., Okada M. Cytotoxicity of unstimulated and thrombin-activated platelets to human tumour cells. Immunology. 1993;78(4):650–6.Sagawa T., Tominaga A., Kodama T., Okada M. Cytotoxicity of unstimulated and thrombin-activated platelets to human tumour cells. Immunology. 1993;78(4):650–6.Ahmad R., Menezes J., Knafo L., Ahmad A. Activated human platelets express Fas-L and induce apoptosis in Fas-positive tumor cells. J Leukoc Biol. 2001;69(1):123–8.Ahmad R., Menezes J., Knafo L., Ahmad A. Activated human platelets express Fas-L and induce apoptosis in Fas-positive tumor cells. J Leukoc Biol. 2001;69(1):123–8.Haemmerle M., Taylor M.L., Gutschner T. et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 2017;8(1):310. https://doi.org/10.1038/s41467-017-00411-z.Haemmerle M., Taylor M.L., Gutschner T. et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 2017;8(1):310. https://doi.org/10.1038/s41467-017-00411-z.Carr B.I., Cavallini A., D’Alessandro R. et al. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer. 2014;14:43. https://doi.org/10.1186/1471-2407-14-43.Carr B.I., Cavallini A., D’Alessandro R. et al. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer. 2014;14:43. https://doi.org/10.1186/1471-2407-14-43.Cho M.S., Bottsford-Miller J., Vasquez H.G. et al. Platelets increase the proliferation of ovarian cancer cells. Blood. 2012;120(24):4869–72. https://doi.org/10.1182/blood-2012-06-438598.Cho M.S., Bottsford-Miller J., Vasquez H.G. et al. Platelets increase the proliferation of ovarian cancer cells. Blood. 2012;120(24):4869–72. https://doi.org/10.1182/blood-2012-06-438598.Hu Q., Sun W., Qian C. et al. Anticancer platelet-mimicking nanovehicles. Adv Mater. 2015;27(44):7043–50. https://doi.org/10.1002/adma.201503323.Hu Q., Sun W., Qian C. et al. Anticancer platelet-mimicking nanovehicles. Adv Mater. 2015;27(44):7043–50. https://doi.org/10.1002/adma.201503323.Papa A.-L., Jiang A., Korin N. et al. Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models. Sci Transl Med. 2019;11(479):eaau5898. https://doi.org/10.1126/scitranslmed.aau5898.Papa A.-L., Jiang A., Korin N. et al. Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models. Sci Transl Med. 2019;11(479):eaau5898. https://doi.org/10.1126/scitranslmed.aau5898.Xu P., Zuo H., Zhou R. et al. Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance. Oncotarget. 2017;8(35):58322–37. https://doi.org/10.18632/oncotarget.16871.Xu P., Zuo H., Zhou R. et al. Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance. Oncotarget. 2017;8(35):58322–37. https://doi.org/10.18632/oncotarget.16871.Haemmerle M., Bottsford-Miller J., Pradeep S. et al. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016;126(5):1885–96. https://doi.org/10.1172/JCI85086.Haemmerle M., Bottsford-Miller J., Pradeep S. et al. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016;126(5):1885–96. https://doi.org/10.1172/JCI85086.Elaskalani O., Berndt M.C., Falasca M., Metharom P. Targeting platelets for the treatment of cancer. Cancers (Basel). 2017;9(7):94. https://doi.org/10.3390/cancers9070094.Elaskalani O., Berndt M.C., Falasca M., Metharom P. Targeting platelets for the treatment of cancer. Cancers (Basel). 2017;9(7):94. https://doi.org/10.3390/cancers9070094.

The authors declare that there are no conflicts of interest present.